Everest Medicines said it has struck an exclusive licence and collaboration with Travere Therapeutics granting Travere exclusive development and commercial rights to EVER001 (civorebrutinib) outside Greater China and certain Southeast Asian countries. Everest will receive a $112.5m upfront payment and is eligible for up to $1.03bn in development, regulatory and commercial milestone payments across up to five indications, plus tiered royalties on future annual net sales ranging from high-single-d

Everest Medicines said it has struck an exclusive licence and collaboration with Travere Therapeutics granting Travere exclusive development and commercial rights to EVER001 (civorebrutinib) outside Greater China and certain Southeast Asian countries. Everest will receive a $112.5m upfront payment and is eligible for up to $1.03bn in development, regulatory and commercial milestone payments across up to five indications, plus tiered royalties on future annual net sales ranging from high-single-digit to low-double-digit pct.